The hypothesis of this study is that children with severe primary immunodeficiencies will benefit from early stem cell transplantation utilizing a reduced intensity conditioning regimen. This regimen is associated with a low risk of complications and will lead to correction of the underlying immunological defects.

Patients on this study will receive 5 days of Fludarabine, 1 day of Busulfan Test Dose, 2 Days of Busulfan Regimen Dose, and 4 days of Anti-Thymocyte Globulin

Other Name: Anti-Thymocyte Globulin is also refered to as ATG.

Eligibility

Ages Eligible for Study:

up to 11 Years (Child)

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Must show one of the following diseases:

SCIDS

Hyper-IgM

Wiskott-Aldrich Syndrome

Chediak-Higashi and Griscelli Syndromes

X-Linked Lymphoproliferative Diseases

IPEX Syndrome

NEMO Syndrome

other severe immunodeficiency diseases not stated above at the discretion of the Principal Investigator

Informed Consent

Adequate Renal Function

Adequate Liver Function

Adequate Cardiac Function

Adequate Pulmonary Function

Adequate Performance Statue

Adequate Venous Access

Exclusion Criteria:

Patient/Family has not signed informed consent

Patient does not have a clear diagnosis of a severe immunodeficiency disease

A suitable donor for the patient cannot be found

Patient is HIV positive

Patient has active Hepatitis B

Patient is pregnant

Patient is considered unsuitable for transplant at the discretion of the Principal Investigators or the medical director

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00613561